Cargando…

Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

Objectives. We aimed at evaluating both the efficacy and safety of TJ-54 (Yokukansan) in patients with treatment-resistant schizophrenia. This randomized, multicenter, double-blind, placebo-controlled study was conducted. Methods. One hundred and twenty antipsychotic-treated inpatients were included...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyaoka, Tsuyoshi, Furuya, Motohide, Horiguchi, Jun, Wake, Rei, Hashioka, Sadayuki, Thoyama, Masaya, Murotani, Kenta, Mori, Norio, Minabe, Yoshio, Iyo, Masaomi, Ueno, Shuichi, Ezoe, Sachiko, Hoshino, Syuzo, Seno, Haruo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411464/ https://www.ncbi.nlm.nih.gov/pubmed/25954314 http://dx.doi.org/10.1155/2015/201592

Ejemplares similares

Yokukansan promotes hippocampal neurogenesis associated with the suppression of activated microglia in Gunn rat
por: Furuya, Motohide, et al.
Publicado: (2013)

Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 12-week prospective, open-label study
por: Miyaoka, Tsuyoshi, et al.
Publicado: (2012)

PT596. The comparison with galantamine and donepezil on Alzheimer’s Disease patients and its relationship with cerebral blood flow
por: Wake, Rei, et al.
Publicado: (2016)

Aceruloplasminemia With Psychomotor Excitement and Neurological Sign Was Improved by Minocycline (Case Report)
por: Hayashida, Maiko, et al.
Publicado: (2016)

Electroconvulsive shock attenuated microgliosis and astrogliosis in the hippocampus and ameliorated schizophrenia-like behavior of Gunn rat
por: Limoa, Erlyn, et al.
Publicado: (2016)

PM375. Electroconvulsive shock ameliorated the schizophrenia-like behavior and attenuated the glial activation in the hippocampus of Gunn Rat
por: Abdul Aziz, Erlyn Limoa Ilhamuddin, et al.
Publicado: (2016)

PM351. Efficacy and Safety of Sansoninto for Insomnia in Child and Adolescent Patients: An Open-Label Study
por: Miyaoka, Tsuyoshi, et al.
Publicado: (2016)

Implications of Systemic Inflammation and Periodontitis for Major Depression
por: Hashioka, Sadayuki, et al.
Publicado: (2018)

PM363. The effect of Ketamine: Gunn rat as a Schizophrenia animal model
por: Hayashida, Maiko, et al.
Publicado: (2016)

PS147. Gunn rats show depression-like behavior and microglial activation in the hippocampus
por: Arauchi, Ryosuke, et al.
Publicado: (2016)

The Possible Causal Link of Periodontitis to Neuropsychiatric Disorders: More Than Psychosocial Mechanisms
por: Hashioka, Sadayuki, et al.
Publicado: (2019)

Salivary Alpha-Amylase Activity Levels in Catatonic Schizophrenia Decrease after Electroconvulsive Therapy
por: Kanayama, Misako, et al.
Publicado: (2018)

Contribution of “Genuine Microglia” to Alzheimer's Disease Pathology
por: Hashioka, Sadayuki, et al.
Publicado: (2022)

Remission of Psychosis in Treatment-Resistant Schizophrenia following Bone Marrow Transplantation: A Case Report
por: Miyaoka, Tsuyoshi, et al.
Publicado: (2017)

Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model
por: Liaury, Kristian, et al.
Publicado: (2012)

Yokukansan enhances the proliferation of B65 neuroblastoma
por: Nakatani, Yoshihiko, et al.
Publicado: (2016)

Decreased Clostridium Abundance after Electroconvulsive Therapy in the Gut Microbiota of a Patient with Schizophrenia
por: Kanayama, Misako, et al.
Publicado: (2019)

Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report
por: Izuhara, Muneto, et al.
Publicado: (2018)

Do Alzheimer's Disease Risk Gene Products Actually Act in Microglia?
por: Hashioka, Sadayuki, et al.
Publicado: (2020)

May Salivary Alpha-Amylase Level Be a Useful Tool for Assessment of the Severity of Schizophrenia and Evaluation of Therapy? A Case Report
por: Ieda, Masa, et al.
Publicado: (2012)

Medication Overuse Headache Successfully Treated by Japanese Herbal Kampo Medicine, Yokukansan
por: Katsuki, Masahito, et al.
Publicado: (2021)

Antiallodynic Effect of Herbal Medicine Yokukansan on Peripheral Neuropathy in Rats with Chronic Constriction Injury
por: Suzuki, Yasuyuki, et al.
Publicado: (2012)

Yokukansan and Yokukansankachimpihange Ameliorate Aggressive Behaviors in Rats with Cholinergic Degeneration in the Nucleus Basalis of Meynert
por: Tabuchi, Masahiro, et al.
Publicado: (2017)

PS28. The effect of Yokukansan, a traditional herbal medicine, on sleep disturbances in elderly patients with neurotic disorders
por: Shinno, Hideto, et al.
Publicado: (2016)

Ameliorating effect of Yokukansan on the development of atopic dermatitis-like lesions and scratching behavior in socially isolated NC/Nga mice
por: Funakushi, Naoko, et al.
Publicado: (2011)

Parvalbumin-positive GABAergic interneurons deficit in the hippocampus in Gunn rats: A possible hyperbilirubinemia-induced animal model of schizophrenia
por: Hayashida, Maiko, et al.
Publicado: (2019)

PT661. The effect of Yokukansan, a traditional herbal medicine, on sleep disturbances and anxiety symptoms in restless legs syndrome
por: Shinno, Hideto, et al.
Publicado: (2016)

Gunn rats with glial activation in the hippocampus show prolonged immobility time in the forced swimming test and tail suspension test
por: Arauchi, Ryosuke, et al.
Publicado: (2018)

Yokukansan and its ingredients as possible treatment options for schizophrenia
por: Yu, Chuan-Hsun, et al.
Publicado: (2014)

Potential Application of Yokukansan as a Remedy for Parkinson's Disease
por: Jang, Jung-Hee, et al.
Publicado: (2018)

The Effect of the Kampo Medicine Yokukansan on Preoperative Anxiety and Sedation Levels
por: Arai, Young-Chang, et al.
Publicado: (2014)

Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer’s Disease
por: Hashioka, Sadayuki, et al.
Publicado: (2021)

Yokukansan Alleviates Cancer Pain by Suppressing Matrix Metalloproteinase-9 in a Mouse Bone Metastasis Model
por: Nakao, Kenta, et al.
Publicado: (2019)

Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
por: Takeyoshi, Kenji, et al.
Publicado: (2016)

Antistress effects of Kampo medicine “Yokukansan” via regulation of orexin secretion
por: Katahira, Haruto, et al.
Publicado: (2017)

Kampo Formulae for the Treatment of Neuropathic Pain ∼ Especially the Mechanism of Action of Yokukansan ∼
por: Sunagawa, Masataka, et al.
Publicado: (2021)

Prevention of delirium with agitation by yokukansan in older adults after cancer surgery
por: Sadahiro, Ryoichi, et al.
Publicado: (2022)

A Case of Pseudohyperaldosteronism Induced by Yokukansan and Shakuyakukanzoto That Resulted in Severe Hypokalemia
por: Arai, Mika, et al.
Publicado: (2023)

Corrigendum to “Yokukansan Alleviates Cancer Pain by Suppressing Matrix Metalloproteinase-9 in a Mouse Bone Metastasis Model”
por: Nakao, Kenta, et al.
Publicado: (2019)

The Japanese Herbal Medicine Yokukansan Exerted Antioxidant and Analgesic Effects in an Experimental Rat Model of Hunner-Type Interstitial Cystitis
por: Inoue, Tatsuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nt0noj99kh63vpdk4f972pu5oj